EUCTR2007-006055-39-FI进行中（未招募）不适用
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 540
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Has given written informed consent before any study-related activity is performed. A study-related activity is defined as any procedure that would not have been performed during the normal management of the patient.
- •2. Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages), in which androgen ablation treatment, except for neoadjuvant hormonal therapy, is indicated. This includes patients with rising PSA after having undergone prostatectomy or radiotherapy with curative intention.
- •3. Is a male patient aged 18 years or older.
- •4. Has a screening serum testosterone level above the lower limit of normal range, globally defined as >2.2 ng/mL.
- •5. Has an ECOG (Eastern Co-operative Oncology Group) score of =2 (see Section 5.2.5).
- •6. Has a screening PSA value of =2 ng/mL.
- •7. Has a life expectancy of at least one year.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Has had previously or is currently under hormonal management of prostate cancer (surgical castration or other hormonal manipulation, including GnRH receptor agonists, GnRH receptor antagonists, anti-androgens, estrogens). However, for patients having undergone prostatectomy or radiotherapy with curative intention, then neoadjuvant/adjuvant hormonal therapy for a maximum duration of 6 months is accepted. This treatment should have been terminated at least 6 months prior to Screening Visit.
- •2. Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy.
- •3. Has a history of severe uncontrolled asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
- •4. Has hypersensitivity towards any component of the investigational medicinal product.
- •5. Has a marked baseline prolongation of QT/QTcF interval (e.g. repeated demonstration of a QTcF interval >450 ms).
- •6. Has a history of risk factors for Torsade de Pointes ventricular arrhythmias (e.g. heart failure, hypokalemia, or family history of Long QT Syndrome).
- •7. Is taking concomitant medications that prolong the QT/QTcF interval.
- •8. Has had cancer within the last five years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin.
- •9. Has a known or suspected clinically significant liver and/or biliary disease.
- •10. Has any clinically significant laboratory abnormalities which in the judgment of the investigator would affect the patient’s health or the outcome of the study.
- •11. Has a clinically significant disorder (other than prostate cancer) or any other condition, including alcohol or drug abuse, which may affect the patient’s health or the outcome of the study as judged by the investigator.
- •12. Has a mental incapacity or language barriers precluding adequate understanding or co-operation.
- •13. Has received an investigational drug within the last 28 days preceding Screening Visit or longer if considered to possibly influence the outcome of the current study.
- •14. Has previously participated in any degarelix study.
研究者
相似试验
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation TherapyMedDRA version: 9.1Level: LLTClassification code 10007113Term: Cancer of prostateProstate CancerEUCTR2007-006055-39-HUFerring Pharmaceuticals A/S540
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation TherapyMedDRA version: 9.1Level: LLTClassification code 10007113Term: Cancer of prostateProstate CancerEUCTR2007-006055-39-BEFerring Pharmaceuticals A/S540
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation TherapyProstate CancerEUCTR2007-006055-39-CZFerring Pharmaceuticals A/S540
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation TherapyProstate CancerEUCTR2007-006055-39-SEFerring Pharmaceuticals A/S540
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation TherapyEUCTR2007-001650-77-HUFerring Pharmaceuticals A/S120